Journal
qf Chromatography,
476 (1989) 93- 98
Elsevier Science Publishers B.V., Amsterdam CHROMSYMP.
Printed in The Netherlands
1612
HIGH-PERFORMANCE
LIQUID
CHROMATOGRAPHY
FOR CYCLOSPORIN MEASUREMENT:
COMPARISON WITH RADIOIMMUNOASSAY
MARIO PLEBANI, MAURIZIO MASIERO, CARLO
DIEGO FAGGIAN and ANGELO BURLINA*
Cattedra di Chimica e M icroscopia
Clinica, Laboratorio
D. PALEARI,
Centrale di Anal&
LAURA
SCIACOVELLI,
Universitti di Padova, Via
Giustiniani 2, 35128 Padova (Italy )
SUMMARY
The large inter-patient variability in cyclosporin pharmacokinetics coupled with
the agent’s narrow therapeutic index with adverse effects resulting from supratherapeutic levels, necessitates individualization of drug dosage and therapeutic
monitoring of cyclosporin blood levels. The performance of a liquid chromatographic
method for the measurement of cyclosporin was evaluated and the results obtained by
this method and by a specific radioimmunoassay
were correlated. The method
described is sensitive, selective, reproducible and easier to perform than other
chromatographic methods. It is suitable for the daily measurement of cyclosporin in
batches of up to 40 samples and the results correlate well with another chromatographic method and with the specific radioimmunoassay.
INTRODUCTION
Cyclosporin A (CsA) is widely used as an effective and potent immunosuppressant in organ transplantation’,2 and treatment with CsA has greatly improved
the results of kidney, heart, bone marrow and liver transplantation. However, the
narrow therapeutic index and the wide variability in its pharmacokinetics necessitate
individualized dosage adjustment3. Well known adverse effects of drug levels above
that range include nephrotoxicity, neurotoxicity, hypertension, gingival hyperplasia,
anorexia, nausea and ileus4. On the other hand, levels below the appropriate range are
associated with an enhanced risk of graft rejection or graft ver.ruShost disease in bone
marrow transplants. For these reasons, careful attention to the CsA concentration in
blood is essential for optimization of therapy.
Several techniques [radioimmunoassay (RIA) with polyclonal and monoclonal
antibodies, high-performance
liquid chromatography
(HPLC) and fluorescence
polarized immunoassay (FPIA)] for therapeutic monitoring of CsA have been
deve10ped5. RIA with polyclonal antiserum and FPIA measure CsA together with
some cross-reactive metabolites that appear in blood after the drug is administered. In
contrast, HPLC and the new RIAs with monoclonal antibodies specifically measure
the parent drug, independent of its metabolites. Specific measurement of CsA seems to
0021- 9673/89/$03.50
0
1989
Elsevier Science Publishers B.V.
94
M. PLEBANI
et al.
be recommended, as suggested by recent paper@. The aim of this work was to evaluate
the performance of isocratic HPLC for the measurement of CsA and to compare the
results with those obtained by a specific radioimmunoassay.
EXPERIMENTAL zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCB
Sam p le s
Whole-blood samples were taken from 80 renal and 60 heart transplant patients
who had received immunotherapy with CsA. CsA (5-20 mg/kg body weight) was given
orally, once or twice a day, and all blood specimens were collected before the next dose.
Samples were collected in tubes containing EDTA-K3 (Merck-Bracco, Milan, Italy) as
an anticoagulant and stored at -20°C until analysed. All samples were analysed by
three different methods for CsA measurement (specific RIA, reference HPLC and
described HPLC). zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFED
Chemical and reagents
Cyclosporin A (CsA) and the internal standard, cyclosporin D (CsD), were
obtained from Sandoz (Basle, Switzerland). Acetonitrile, hexane, methanol and water
(HPLC grade) were purchased from Merck-Bracco.
Instrumentation and chromatographic conditions
A Bio-Rad HPLC instrument was employed (Bio-Rad Labs., Segrate, Italy),
including a Model 1330 HPLC dual piston pump, Model 1306 variable-wavelength
UV detector, Model AS-48 autosampler and Model 3392 A integrator. The column
used was a reversed-phase Cs mini-column (high-performance RP mini-column, 30 x
4.6 mm I.D., particle size 5 pm, from Bio-Rad Labs.), maintained at 70°C with
a column heater (Bio-Rad Labs.). The flow-rate of the mobile phase (20 mM
ammonium phosphate buffer in 56% aqueous acetonitrile, pH 6.2) was 1.2 ml/min.
The effluent from the column was monitored at 210 nm.
Preparation of extraction columns
The extraction of CsA involved the use of l.O-ml disposable cyano extraction
columns (40~pm mean particle size) (Analytichem International, Harbor City, CA,
U.S.A.). These columns were prepared by washing with 3 ml of 15% acetonitrile under
vacuum. A Vat-Elut SPS 24 vacuum chamber, designed to accept 24 extraction
column simultaneously, was purchased from Analytichem International.
Procedure
We employed the method of Sivorinowsky et a1.73*for the HPLC measurement
of CsA, with the following modifications. A l.O-ml volume of of water and 2.0 ml of
working internal standard solution (CsD in a 30% aqueous acetonitrile solution) are
pipetted into 1.0 ml of whole-blood samples, controls and standards, followed by
vortex mixing for 30 s and centrifugation for 10 min at 1000 g at 0°C. A 3.0-ml volume
of blood supernatant is applied to the columns, which are drained under vacuum.
Excess blood is washed off the column with 15% acetonitrile (three l.O-ml volumes)
and each column is rinsed with 4.0 ml of 50% acetonitrile to remove hydrophobic
contaminants. The cyclosporins are eluted with 450 ~1 of ethanol into small
HPLC OF CYCLOSPORIN
95
borosilicate test-tubes. The eluate is diluted with 200 ~1of 10M3Mzyxwvutsrqponmlkjihgfed
phosphoric acid and
washed twice with 600 ~1of hexane. After centrifugation (1 min at 500 g), the hexane is
removed by aspiration and 100 ~1 of the eluate are injected into an isocratic HPLC
system consisting of a reversed-phase Cs minicolumn and the buffered acetonitrile
mobile phase (pH 6.2) at 70°C. The quantitation is based on comparison of the
CsA/CsD (internal standard) peak-height ratio in the unknown sample to the ratio in
the whole-blood standard.
Interferences
We evaluated potential interferences in this analysis by chromatographing pure
drug solutions and samples of whole blood from patients who had ingested various
drugs.The drugs tested under these conditions were acetaminophen, aminotriptyline,
caffeine, chloramphenicol, chlordiazepoxide, diazepam, ethosuximide, gentamicin,
imipramine, pentobarbital, phenobarbital, phenytoin, primidone, salicylate, secobarbital, theophylline and cortisone analogues (prednisone, prednisolone and methylprednisolone). We also evaluated the interference of metabolite 17 of CsA (generously
supplied by Dr. Maurer, Sandoz).
Recovery
CsA was added to a drug-free whole-blood pool in amounts equivalent to
100-1500 pg/l, and the analytical recovery was calculated.
Comparison methods
HPLC according to Carruthers et al. ‘. This method employs extraction with
diethyl ether and chromatography on a 25 cm x 4.8 mm I.D. Ultrasphere-Octyl(5 pm)
column (Beckman Analytical, Milan, Italy) maintained at 72°C.
RIA with monoclonal antibodies. We utilized a radioimmunoassay
with a mice
monoclonal antibody that did not react appreciably with the metabolites of CsA. The
method utilizes an iodinated tracer and a double antibody for separating bound and
free fractions (Cycle-Trac sp, Incstar Corp., Stillwater, MN, U.S.A.).
Statistics
The comparison between methods was made by regression analysis with an
F-test on variance; the difference in slope from unity was assessed by Student’s t-test.
RESULTS
As shown in Fig. 1, the retention times of CsA and of the internal standard CsD
are 6.0 and 8.5 min, respectively. No interfering peaks eluting at times that would
interfere with the analysis were detected in samples from patients who had received
CsA together with commonly used drugs. The precision of the method is shown in
Table 1. The results of the analytical recovery test carried out on samples spiked with
CsA are illustrated in Table II. The lower limit of sensitivity (signal equal to twice the
baseline noise) of our procedure is 25 pg/l.
In order to simplify the original method, we tried to eliminate the double
extraction with hexane by introducing directly 1.0 ml of hexane (twice) into the
extraction column. The results obtained were not significantly different from those
M. PLEBANI
96
et al. zyxwvu
AU FS
0 .0 1
0
Fig.
zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLK
m in
I. Chromatogram
TABLE
12
6
of extracted
whole-blood
sample.
460 pg/l.
I
REPRODUCIBILITY
Parameter
STUDIES
x
S.D.
(Ml)
(Al)
Coefficient qf
variation (%)
Within-run
precision
(n = 21)
IS0
470
805
3.5
11.2
21.7
2.3
2.4
2.7
Between-run
precision
(n = 11)
14s
468
810
8.6
23.8
39.0
5.9
5.1
4.8
TABLE
CsA concentration,
II
ANALYTICAL
Calculated
value
RECOVERY
Observed
value”
Recovery
(%) b
(Mll)
(Mll) zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA
100.0
200.0
500.0
1000.0
104.0
205.0
506.0
984.0
f
&
+
+
4.0
4.9
13.4
26.4
’ Mean of three determinations
* Mean value.
104.0
102.5
101.0
98.4
k standard
deviation.
HPLC
97 zyxwvu
OF CYCLOSPORIN
600.
04
0
.,,,,
100
,
200
,
300
,
,
400
HPLC
,
500
,.
600
,
700
6
0
@g/l)
Fig. 2. Results of simultaneous
analysis of whole-blood
samples by HPLC and specific RIA [n = 137;
r = 0.974 (p < 0.0001); y = 1.037x + 27.17 pg/l; S,., = 27; the slope was not different from I @ = 0.11;
n.s.)].
given by the original method (J > 0.05). No interference from metabolite 17 and the
drugs tested was observed. A high correlation between the results obtained by our
method (j) and that of Carruthers et aL9 (x) was observed [n = 135, r = 0.989,
p < zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHGFEDCBA
0.0001; y = 0.920x + 10.2 pg/l; S,., = 22; the slope was not different from 10, =
0.34; n.s.)]. Moreover, a good correlation was found between our HPLC method and
specific RIA with monoclonal antibodies (Fig. 2).
DISCUSSION
Numerous HPLC methods have been described for the measurement of
CsAi”~“. Despite their specificity, most HPLC determinations of CsA have definite
disadvantages in comparison with RIA. In particular, long analysis times and
difficulties in processing a large number of samples have been reported. Some
procedures require time-consuming multi-step extractions; in some the extraction
efficiency is poor; others have unsatisfactory detection limits. For these reasons, most
laboratories prefere to monitor CsA by RIA.
The chromatographic method evaluated here is suitable for the daily measurement of CsA in batches up to 40 samples of whole blood. Whole blood was chosen
because of the known problem of temperature-dependent separationi2v’ 3 and because
of recent recommendations of the National Academy of Clinical Biochemistry/
American Association for Clinical Chemistry Task Force on Cyclosporin Monitoring6. The extraction is rapid and efficient, and chromatography is completed in 10
min per sample. With the use of a Vat-Elut chamber, designed to accept 24 extraction
columns simultaneously, we are able to process 24 samples of whole blood in less than
30 min. The reproducibility is satisfactory, and 25 pg/l is an adequate sensitivity for
therapeutic drug monitoring.
The principal advantage of our HPLC method is the rapid and simple extraction
procedure compared with other published extraction procedures”,’ ‘. Moreover, the
use of a mini-column is cost effective. The agreement observed between the results
M. PLEBANI
98
et al.
obtained by our HPLC method and specitic RIA demonstrates the accuracy of our
method.
Although specific measurement of CsA is now recommended as a guide to
therapy, some evidence exists that CsA metabolites are immunosuppressiver4 and
even toxic15. Furthermore, differences exist in the metabolic handling of CsA in
different groups of patients. The combination of specific and non-specific measurement of CsA provides a method for investigating the influence of metabolism on
immunosuppressive therapy and its adverse effectsi6. Better information is derived
from the concomitant identification and determination of CsA and its individual
metabolites by HPLC. Recently, Lensmeyer et ~1.” described a chromatographic
method for concomitant profiling of CsA and its metabolites in one assay. Preliminary
results obtained with this selective measurement of CsA metabolites seems to prove the
importance of such a determination for describing the interrelationship of CsA and its
metabolites in therapy and toxicity ‘* . We hope that new HPLC methods for
concomitant measurement of CsA and its metabolites will soon be introduced into
clinical practice.
REFERENCES
Opelz, Prog. Allergy , 38 (1986) 329.
T. Beveridge, Prog. Allergy , 38 (1986) 269.
3 G. J. Burckart. D. M. Canafax and G. C. Yee, Drug Intell. Clin. Pharm., 20 (1986) 649.
4 H. Nogueira and R. Cutler, Dialy sis Transplant. Today, Oct. (1985) 585.
5 D. W. Holt, J. T. Marsden and A. Johnston, Transplant. Proc., 18 (1986) 101.
6 L. M. Shaw, L. Demers, D. Freeman, T. Moyer, A. Sanghui, H. Seltman and R. Vonkataramanan,
1 G.
2
Clin.
Chem., 33 (1987) 1269.
7 G.
Sivorinowsky, S. R. Binder, M. J. Regalia and M. E. Biaggi,
Ann. Cl&. Biochem., 24,
Suppl. 2 (1987)
64.
8
9
10
11
12
13
14
15
16
17
18
Test, Instruction M anual, Bio-Rad Clinical Division, Richmond, CA,
1986.
S. G. Carruthers, D. J. Freeman, T. G. Koepler, W. Howson, P. A. Keown, A. Laupacls and C. R.
Stiller, Clin. Chem., 29 (1983) 180.
T. P. Moyer, P. Johnson, S. M. Faynor and S. Sterioff, Clin. Biochem., 19 (1986) 83.
S. J. Fletcher and R. A. Bacchus, Ann. Clin. Biochem., 25 (1988) 510.
M. Wenk, F. Follath and E. Abish, Clin. Chem., 29 (1983) 1865.
H. Dieperik, Lancet, i (1983) 416.
B. Freed, T. Rosano and N. Lempert, Transplantation, 43 (1987) 123.
A. Wood and M. Lemaire, Transplant. Proc., 17 (1985) 27.
M. Plebani and A. Burlina, Lancer, ii (1988) 687.
G. Lensmeyer, D. A. Wiebe and 1. H. Carlson, Clin. Chem., 33 (1987) 1841.
C. Lensmeyer, D. A. Wiebe and I. H. Carlson, Clin. Chem., 33 (1987) 1851.
Bio-Rud Cy closporin by HPLC